Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Sino Biopharm’s invoX Acquires F-Star, a UK Bispecific Company, for $161 Million

publication date: Jun 23, 2022

invoX Pharma, a Sino Biopharm subsidiary, will pay $161 million to acquire F-Star, a Cambridge, UK clinical stage company developing bispecific drugs for immunotherapies. F-star’s platform technology pioneers the use of tetravalent (2+2) bispecific antibodies. These antibodies target two different antigens and are paired with a unique set of pharmacology agents to activate an immune reaction in the tumor microenvironment. F-Star has four candidates in clinical trials, three from its tetravalent platform and one next-gen STING agonist. invoX, located in the UK, is responsible for Sino Biopharma’s R&D and business development outside of China. More details....

Stock Symbols: (HK: 1177) (NSDQ: FSTX)

Share this with colleagues: